News | September 22, 2009

Robotic Stereotactic Radiotherapy Safe Alternative to Fractionated Radiotherapy

September 22, 2009 - Robotic stereotactic radiotherapy appeared to be a safe and obviously superior alternative to conventionally fractionated radiotherapy in a small cohort of patients with stage I non-small cell lung cancer (NSCLC), according to a study published in the October issue of Clinical Oncology.

In the study, researchers set out to determine the effectiveness of robotic stereotactic radiotherapy with image guidance and real-time respiratory tracking against early stage peripheral lung cancer.

All patients with stage I non-small cell lung cancer (NSCLC) were treated using CyberKnife. All patients had co-morbid conditions that precluded lobectomy. The clinical target volume (CTV) included the gross tumour volume (GTV) and a 6 mm margin in all directions to account for microscopic extension. The planning target volume (PTV) equalled CTVD + 2 mm in all directions for uncertainty. Tumor motion was tracked using a combination of Synchrony and Xsight Spine tracking methods with the aid of a single gold marker implanted in the center of the tumor, or using the newer Xsight Lung method without markers for selected tumors. A 60-67.5 Gy dose was prescribed to the 60-80 percent isodose line (median 65 percent) and given in three to five fractions. Patients were followed every 3 months for a median of 27.5 months (range 24-53 months).

Of the 67 patients with NSCLC stage IA or IB treated between January 2004 and December 2008, investigators reported the results of a cohort of 31 with peripheral stage I tumors of 0.6-71 cm3 volume treated between January 2004 and December 2007 with total doses between 60 and 67.5 Gy in three to five fractions. The median Dmax was 88.2 Gy and the median V95 of the PTV was 99.6 percent or 27.9 cm3. No grade 3 or above toxicity was encountered. Four cases of radiation pneumonitis and one case of oesophagitis were observed. In those patients whose pre- and post-treatment results were available, no change in pulmonary function tests was observed. Actuarial local control was 93.2 percent for 1 year and 85.8 percent for up to 4.5 years. One-year overall survival was 93.6 percent and 83.5 percent for up to 4.5 years, as projected by Kaplan-Meier analyses.

The researchers concluded that in this small cohort of patients with stage I peripheral NSCLC, robotic stereotactic radiotherapy seems to be a safe and obviously superior alternative to conventionally fractionated radiotherapy, with results that may be approaching those obtained with lobectomy without the associated morbidity.

Reference: Brown, W.T., Wu, X., Fayad, F., Fowler, J.F., García, S., Monterroso, M.I., de la Zerda, A., Schwade, J.G. Application of Robotic Stereotactic Radiotherapy to Peripheral Stage I Non-Small Cell Lung Cancer With Curative Intent. Clin Oncol. 2009 Oct 1;21(8):623-631.

Related Content

Insightec Announces Expanded Reach of MR-Guided Focused Ultrasound
News | Focused Ultrasound Therapy | August 22, 2017
Insightec announced recently that worldwide adoption of magnetic resonance (MR)-guided focused ultrasound continues to...
UCLA Study Offers Roadmap to Personalized Therapies for Sarcoma
News | Oncology Diagnostics | August 22, 2017
A new UCLA study is the first to identify patient and tumor characteristics that predict the successful creation of...
Sponsored Content | Videos | Information Technology | August 22, 2017
Melissa Martin, MS, president of the American Association of Physicists in Medicine (AAPM), discusses her vision of t
Sponsored Content | Videos | Proton Therapy | August 21, 2017
Mark Pankuch, Ph.D., director of medical physics at the Northwestern Medicine Chicago Proton Center, discusses the cl
Summit Cancer Center-Boise Treats First Cancer Patients With Accuray Radixact System
News | Image Guided Radiation Therapy (IGRT) | August 21, 2017
Accuray Inc. and the Summit Cancer Center-Boise announced that the center is now treating patients with the Radixact...
MedStar Georgetown Proton Center Selects RayStation for Treatment Planning
News | Treatment Planning | August 17, 2017
August 17, 2017 — The proton center at MedStar Georgetown University Hospital will utilize RayStation for planning on
DOSIsoft Releases ISOgray Proton Therapy Treatment Planning System
Technology | Treatment Planning | August 15, 2017
DOSIsoft SA announced the official release, with CE marking, of ISOgray Treatment Planning System (TPS) release 4.3 for...
First Radixact Results Presented at AAPM 2017
News | Radiation Therapy | August 10, 2017
Accuray Inc. announced that the first studies validating the benefits of the Radixact System were presented at the 59th...
Clinical Data Supports Use of Xoft System for Endometrial Cancer
News | Brachytherapy Systems | August 03, 2017
Researchers presented clinical data supporting use of the Xoft Axxent Electronic Brachytherapy (eBx) System for the...
Overlay Init